Clinical trials: Osteogenesis Imperfecta
Osteogenesis Imperfecta
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
This protocol was a prospective, Phase I study of allogeneic bone marrow transplantation (BMT) as the primary therapy for Osteogenesis Imperfecta Types II and III.
- Trial name
- NCT00705120
- Testing
- Bone Marrow Cell Transplantation, Irradiation, Total Body, Cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- St. Jude Children's Research Hospital
Osteogenesis Imperfecta
Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta
The purpose of this study is to determine the safety and effectiveness of five infusions of characterized HLA-identical MSC in non immunosuppressed children with Osteogenesis Imperfecta (OI).
- Trial name
- TERCELOI (NCT02172885)
- Testing
- Mesenchymal Stem Cells
- Where
- 2 sites in Spain
- Volunteers
- 2 people
- Sponsor
- Hospital de Cruces
Osteogenesis Imperfecta
Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708
Osteogenesis imperfecta (OI) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the United States. OI varies in severity from perinatally lethal to mild forms.
- Trial name
- NCT05317637
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Baylor College of Medicine
Meniscus Tear, Knee Meniscus Injury
High-Purity Type I Collagen Augmentation in Meniscal Repair
This prospective, single-arm feasibility study evaluates the safety, procedural feasibility, and early clinical outcomes of High-Purity Type I Collagen used as an adjunct in arthroscopic meniscal repair.
- Conditions
- Meniscus Tear, Knee Meniscus Injury, Meniscal Repair, Knee Arthroscopy (for Diagnostic or Therapy)
- Trial name
- NCT07352410
- Testing
- High-Purity Type I Collagen
- Where
- India
- Volunteers
- 18 people
- Sponsor
- Adichunchanagiri Institute of Medical Sciences, B G Nagara
Knee Osteoarthritis, Gonarthrosis
Collagen-PVP vs Hylan G-F 20 in the Treatment of Knee Osteoarthritis
Articular cartilage degradation is the main characteristic of osteoarthritis (OA), involving enzymatic and inflammatory mechanisms that change it into a chronic disease.
- Trial name
- NCT04019782
- Testing
- Collagen-PVP, Hylan G-F 20
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Bone Disease, Metabolic
Diagnosis of Osteogenesis Imperfecta in Children
The study will be conducted at Assiut university children hospital and it will include patients with history of repeated fractures due to mild or irrelevant trauma.
- Trial name
- NCT03169192
- Testing
- Zoledronic Acid
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Assiut University
Osteogenesis Imperfecta
Osteogenesis Imperfecta and Balance
Osteogenesis Imperfecta (OI), also known as brittle bone disease, is a group of genetic disorders that mainly affect the bones. It results in bones that break easily. Its severity may be mild to severe.
- Trial name
- NCT06010134
- Testing
- Physical Therapy Program
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- South Valley University
Osteogenesis Imperfecta, Osteogenesis Imperfecta Type III
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
This is a Phase 1/2 study to determine the safety and efficacy of allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3.
- Trial name
- NCT05559801
- Testing
- Bone marrow-derived mesenchymal stromal cells (MSCs)
- Volunteers
- 12 people
- Sponsor
- Emory University
Osteogenesis Imperfecta (OI)
Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN)
This study will determine the effect of treatment of AGA2115 in adults with Type I, III, or IV osteogenesis imperfecta versus placebo.
- Trial name
- IDUN (NCT07062588)
- Testing
- AGA2115
- Where
- 26 sites in United States, Argentina and 6 more
- Volunteers
- 80 people
- Sponsor
- Angitia Incorporated Limited
Osteogenesis Imperfecta
Urinary Biomarkers of OI Pathobiology
Osteogenesis imperfecta (OI) is a rare inherited disorder that causes bones to break easily. Individuals with osteogenesis imperfecta break bones often and may have other problems, including hearing loss, dental problems, pain…
- Trial name
- NCT02531087
- Where
- 7 sites in United States, Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Myofascial Pain Syndrome - Neck, Spondyloarthrosis
Can Blood Biomarkers of Inflammation and BDNF be Used to Assess the Effectiveness of Collagen Mesotherapy in Chronic CMPS?
The aim of the study is to assess the concentration of anti-inflammatory markers after the use of cervical spine mesotherapy in the course of pain syndrome. The study is randomized.
- Conditions
- Myofascial Pain Syndrome - Neck, Spondyloarthrosis, Neck Pain, Cervical Pain
- Trial name
- NCT06807177
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Osteogenesis Imperfecta, Brittle Bone Disorders
Osteogenesis Imperfecta (OI) Quality of Life Survey Pilot Project 2
The purpose of this study is to explore the patient perspective of disease burden in Osteogenesis Imperfecta (OI). Participants will complete a web-based survey of questions which are usually administered within the…
- Trial name
- NCT02793063
- Testing
- Web-based Survey
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of South Florida
Osteogenesis Imperfecta
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
Osteogenesis imperfecta (OI) is an inherited skeletal disorder characterised by increased risk of fragility fractures. Bisphosphonates are frequently prescribed for adult patients with OI with the aim of preventing fractures but…
- Trial name
- TOPaZ (NCT03735537)
- Testing
- Teriparatide Pen Injector, Zoledronic Acid
- Where
- 23 sites in Ireland, United Kingdom
- Volunteers
- 350 people
- Sponsor
- University of Edinburgh
Osteogenesis Imperfecta
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
Osteogenesis imperfecta (OI) is an inherited disease of the connective tissue. Symptoms are fractures, growth retardation, blue sclera, bad teeth, impaired hearing a.o.
- Trial name
- NCT01679080
- Testing
- Zoledronic acid, Teriparatide, No active treatment
- Where
- 3 sites in Denmark
- Volunteers
- 9 people
- Sponsor
- University of Aarhus
Osteogenesis Imperfecta
Evaluation and Intervention for the Effects of Osteogenesis Imperfecta
We propose a longitudinal study of the natural history of types III and IV osteogenesis imperfecta for children age birth to 25 years.
- Trial name
- NCT00001594
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Osteogenesis Imperfecta
Boost to Brittle Bones - Stem Cell Transplantation for Treatment of Brittle Bones
An exploratory, open label, multiple dose, phase I/II trial (n=15) evaluating safety and efficacy of intravenous and intraosseous infusion of allogeneic expanded fetal mesenchymal stem cells (MSC) for the treatment of severe…
- Trial name
- BOOST2B (NCT04623606)
- Testing
- BOOST cells
- Where
- India
- Volunteers
- 15 people
- Sponsor
- Christian Medical College, Vellore, India
Osteogenesis Imperfecta
Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta
Alendronate should be considered as an alternative therapy of osteogenesis imperfecta (OI) because it significantly increased areal bone mineral density (BMD) and its Z score, decreased fracture incidence, inhibited bone…
- Trial name
- NCT02303873
- Testing
- Alendronate
- Volunteers
- 99 people
- Sponsor
- Peking Union Medical College Hospital
Osteogenesis Imperfecta (OI)
A Dose REgimen-Finding Study of AGA2115 in Chinese Patients With Osteogenesis ImpeRfecta (EIR)
This study is to evaluate the safety and efficacy of AGA2115 at three different dose regimens in Chinese adults and adolescents with Type I, III, or IV Osteogenesis imperfecta (OI).
- Trial name
- EIR (NCT07557446)
- Testing
- AGA2115
- Where
- 5 sites in China
- Volunteers
- 48 people
- Sponsor
- Angitia Biopharmaceuticals Guangzhou Limited
Osteogenesis Imperfecta
Zoledronic Acid in Children (1 -17 Years) With Severe Osteogenesis Imperfecta
This is an extension study to examine the long-term safety and efficacy of zoledronic acid in patients who have completed the core CZOL446H2202 study.
- Trial name
- NCT00131118
- Testing
- Zoledronic Acid
- Where
- 10 sites in United States
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Osteodysplasia
Stromal Therapy of Osteodysplasia After Allogeneic Bone Marrow Transplantation
Osteodysplasia or poorly formed bones, "brittle bones" is a genetic disease with no known proven treatments. Some forms of osteodysplasia may cause severe disability and even death.
- Trial name
- NCT00186914
- Testing
- Marrow stromal cell infusion
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- St. Jude Children's Research Hospital